Histone deacetylase inhibitors promote mitochondrial reactive oxygen ...

3 downloads 119 Views 1MB Size Report
Dec 28, 2015 - Entinostat (Fig. 5). Collectively, these data are consistent with inhibition of HDAC6,. 324 and/or related HDACs, enhancing human macrophage ...
AAC Accepted Manuscript Posted Online 28 December 2015 Antimicrob. Agents Chemother. doi:10.1128/AAC.01876-15 Copyright © 2015, American Society for Microbiology. All Rights Reserved.

1

Histone deacetylase inhibitors promote mitochondrial reactive oxygen

2

species production and bacterial clearance by human macrophages

3 4

Juliana K. Ariffin, Kaustav das Gupta, Ronan Kapetanovic, Abishek Iyer, Robert C.

5

Reid, David P. Fairlie, Matthew J. Sweet#

6 7

Institute for Molecular Bioscience, IMB Centre for Inflammation and Disease Research

8

and Australian Infectious Diseases Research Centre, The University of Queensland,

9

Brisbane, Queensland, 4072 Australia.

10 11

Running Title: HDAC inhibitors boost antimicrobial responses

12 13

#

Address correspondence to Matthew J Sweet, [email protected].

14

1

15

Abstract

16

Broad-spectrum histone deacetylase inhibitors (HDACi) are used clinically as anti-cancer

17

agents, and more isoform-selective HDACi have been sought to modulate other

18

conditions, including chronic inflammatory diseases. Mouse studies suggest that HDACi

19

down-regulate immune responses and may compromise host defence. However, their

20

effects on human macrophage antimicrobial responses are largely unknown. Here we

21

show that overnight pre-treatment of human macrophages with HDACi prior to challenge

22

with Salmonella enterica serovar Typhimurium (S. Typhimurium) or Escherichia coli (E.

23

coli) results in significantly reduced intramacrophage bacterial loads, which likely

24

reflects the fact that this treatment regime impairs phagocytosis. In contrast, co-treatment

25

of human macrophages with HDACi at the time of bacterial challenge did not impair

26

phagocytosis; instead HDACi co-treatment actually promoted clearance of intracellular S.

27

Typhimurium and E. coli. Mechanistically, treatment of human macrophages with

28

HDACi at the time of bacterial infection enhanced mitochondrial reactive oxygen species

29

generation by these cells. The capacity of HDACi to promote clearance of intracellular

30

bacteria from human macrophages was abrogated when cells were pre-treated with

31

MitoTracker Red CMXRos, which perturbs mitochondrial function. The HDAC6-

32

selective inhibitor, tubastatin A, promoted bacterial clearance from human macrophages,

33

whereas the class I HDAC inhibitor, MS-275, which inhibits HDAC1-3, had no effect on

34

intracellular bacterial loads. These data are consistent with HDAC6, and/or related

35

HDACs, constraining mitochondrial reactive oxygen species production from human

36

macrophages during bacterial challenge. Our findings suggest that, whereas long-term

2

37

HDACi treatment regimes may potentially compromise host defence, selective HDAC

38

inhibitors could have applications in treating acute bacterial infections.

3

39

INTRODUCTION

40

Gene expression in eukaryotic cells is controlled by the accessibility of DNA in the form

41

of chromatin wrapped around histone proteins. Histone acetyltransferases (HATs)

42

catalyze acetylation of lysine residues on core histone tails to allow initiation of

43

transcription, whereas histone deacetylases (HDACs) reverse this process by catalyzing

44

the removal of acetyl groups. The latter results in chromatin compaction and silencing of

45

gene transcription, although this is a greatly simplified model of gene regulation (1).

46

HDACs are grouped into distinct classes based on sequence homology to yeast proteins.

47

The classical HDACs are sub-divided into Class I (HDAC1, 2, 3, 8), IIa (HDAC4, 5, 7,

48

9), IIb (HDAC6, 10) and IV (HDAC11) HDACs. They are dependent on zinc for

49

enzymatic activity, share sequence similarity, and most of these enzymes are inhibited by

50

broad-spectrum HDAC inhibitors (HDACi) such as trichostatin A (TSA) and

51

suberoylanilide hydroxamic acid (SAHA) (2). In contrast, non-classical Class III

52

HDACs, or sirtuins, function through a distinct NAD+-dependent mechanism. Although

53

commonly used HDACi such as TSA and SAHA target multiple classical HDACs,

54

isoform-selective HDACi for some individual HDACs have now been described. For

55

example, tubacin and tubastatin A preferentially inhibit HDAC6, whilst MS-275 is most

56

potent on HDAC1, but also inhibits HDAC2 and HDAC3 (2). HDACi have been found to

57

be effective as anti-cancer agents, at least for some cancers such as cutaneous T cell

58

lymphoma, by promoting the expression of tumour suppressor genes and inducing cell

59

differentiation, growth arrest and/or apoptosis (3-6). Although HDACs are termed

60

‘histone’ deacetylases, they also act on numerous non-histone proteins such as

4

61

transcription factors, cell cycle proteins and protein kinases (7). Hence, HDACi have

62

many effects beyond the regulation of epigenetic states and gene expression.

63 64

Beyond their anti-cancer applications, HDACi have been investigated as therapeutic

65

agents in models of acute and chronic inflammatory diseases (3, 8-10). HDACi are

66

reported to inhibit pro-inflammatory cytokine secretion via multiple mechanisms, for

67

example inhibiting the transcriptional activity of HIF-1α (8, 11), impairing recruitment of

68

pro-inflammatory transcription factors to target promoters (12), reducing the stability of

69

mRNAs encoding inflammatory cytokines (13), and upregulating the expression and

70

activity of the transcriptional repressor complex, Mi-2/NuRD (14). Such studies imply

71

that certain HDACs have pro-inflammatory functions, and indeed this has been reported

72

for a number of HDACs, for example HDAC4 (15) and HDAC7 (11). As pro-

73

inflammatory cytokines play important roles in host defense, it is a distinct possibility

74

that HDACi could, in dampening inflammation, also compromise host defence. Indeed,

75

this is a major limitation of many existing anti-inflammatory agents, including anti-TNFα

76

therapy used to treat patients with rheumatoid arthritis and inflammatory bowel disease

77

(16-18).

78 79

Previous studies examining the effects of HDACi on innate immune responses in mouse

80

macrophages reported that treatment with the broad spectrum HDACi, TSA and valproic

81

acid, reduced expression of phagocytic receptors, NADPH oxidase subunits and inducible

82

nitric oxide synthase (19). Consequently, HDACi impaired phagocytotic activity of

83

mouse bone marrow-derived macrophages, as well as production of reactive oxygen

5

84

species (ROS) and nitric oxide. Furthermore, the ability of mouse macrophages to clear

85

Escherichia coli (E. coli) and Staphylococcus aureus upon challenge was compromised

86

(19). A genome-wide microarray analysis of gene expression profiles from murine

87

macrophages and dendritic cells stimulated with toll-like receptor (TLR) agonists also

88

revealed that TSA treatment impaired up to 60% of TLR2 and TLR4 target genes,

89

including

90

molecules, transcription regulators and kinases, while only 16% of genes were

91

upregulated (14). However, studies on the impacts of HDACi on host immunity have

92

primarily utilized mouse models or mouse cells, and effects on host defence in humans

93

have not been intensively investigated. Although human and mouse innate immune

94

responses are broadly conserved, some phenotypic differences, divergence in gene

95

repertoires and differential regulation of orthologous genes have been noted between

96

humans and mice (20-23). Here we report that, whilst long-term treatment of human

97

macrophages with HDACi impairs the phagocytic capacity of human macrophages, acute

98

treatment with HDACi at the time of bacterial infection actually enhances mitochondrial

99

ROS production from these cells, which correlated with increased antibacterial responses.

pattern

recognition

receptors,

cytokines,

chemokines,

co-stimulatory

100

6

101

MATERIALS AND METHODS

102

Materials. TSA purified from Streptomyces sp. (Sigma Aldrich) was dissolved in 100%

103

ethanol, stored at 4˚C, and diluted in tissue culture media to be used at the indicated

104

concentrations. SAHA was synthesized in-house, dissolved in DMSO, stored at -20˚C,

105

and diluted in tissue culture media to be used at 10 µM. Tubastatin A (Sigma Aldrich)

106

and MS-275 (synthesised in-house) were dissolved in DMSO to 30 mM, stored at -20˚C

107

and used at 20 µM. MitoTracker® Red CMXRos (Life Technologies) was stored at -20˚C

108

and dissolved in DMSO to 1 mM before further dilution in tissue culture media for

109

treatment of cells. Human recombinant IFN-γ (R&D Systems) was stored at a

110

concentration of 2.5 µg/mL at -20˚C and diluted in tissue culture media to a final

111

concentration of 2.5 ng/mL. Cytochalasin D (Life Technologies) was dissolved in DMSO

112

to 2 mM, stored at -20˚C, and used at 10 µM. MitoSOXTM Red mitochondrial superoxide

113

indicator (Life Technologies) was dissolved in DMSO to 5 mM, stored at -20˚C, and used

114

at 5 µM. pHrodo® Green E. coli BioParticles® Conjugate (Invitrogen) was dissolved in

115

PBS to 1 mg/ml, sonicated for 5 minutes, vortexed for 1 minute, then stored at -20˚C.

116 117

Ethics statement. Before undertaking the studies described, approval for all experiments

118

using primary human cells was obtained from the Medical Research Ethics Committee of

119

the University of Queensland (Approval number 2013001519).

120 121

Cell isolation and culture. Human monocyte-derived macrophages (HMDM) were

122

prepared from CD14+ monocytes from Red Cross blood donors. In brief, CD14+

123

monocytes were differentiated into HMDM, by culture with 1x104 U/mL CSF-1 for 6

7

124

days, as previously described (22, 24). On day 6, HMDM were harvested and re-plated,

125

in the presence of CSF-1, for experimentation. THP-1 cells were cultured as previously

126

described (25), differentiated for 48 h with 30 ng/mL phorbol 12-myristate 13-acetate

127

(PMA, Sigma Aldrich) and rested for 4 h before experimentation. All cells were cultured

128

in an incubator at 37˚C with 5% CO2.

129 130

Bacterial culture. The Salmonella enterica serovar Typhimurium (S. Typhimurium) SLI

131

344 (26) and E. coli MG1655 (27) strains were stored in LB broth containing 50% sterile

132

glycerol at -80˚C. The appropriate multiplicity of infection (MOI) for infection assays

133

was calculated by spectrophotometry analysis of bacteria cell density from an isolated

134

colony grown overnight in LB broth. Possible effects of HDACi on S. Typhimurium and

135

E. coli growth were assessed by spectrophotometric analysis of bacterial cultures grown

136

at 37˚C in complete HMDM media at the indicated time points.

137 138

In vitro infection assays. Bacterial infection assays were conducted in HMDM and

139

PMA-differentiated THP-1 macrophages to assess intracellular bacterial loads, as

140

previously described (28). In brief, cells were cultured at 4x105 cells/well in 1 mL

141

antibiotic-free tissue culture media at 37˚C, then either primed with HDACi for 18 h prior

142

to bacterial challenge (S. Typhimurium or E. coli; MOI 100), or co-treated with HDACi

143

at the time of infection. At 1 h post-infection, cells were washed with media containing

144

200 µg/mL gentamicin to exclude extracellular bacteria, then maintained in media

145

containing 20 µg/mL gentamicin. In situations where cells were treated with

146

pharmacological reagents, inhibitors were re-added to the media containing 20 µg/mL

8

147

gentamicin and maintained throughout the incubation period. At appropriate time points,

148

media were replaced with 0.01% Triton X-100 in PBS and cells were lysed by pipetting.

149

Diluted lysates were cultured on agar plates at 37˚C overnight, and colony counts were

150

used to assess intracellular bacterial loads. In some experiments, supernatants were

151

harvested at the indicated time points to assess cell death through the release of the

152

metabolic enzyme, lactate dehydrogenase (LDH), from dying cells into culture

153

supernatants. LDH release was quantified by measuring LDH in culture supernatants in

154

comparison to total LDH (LDH present in supernatants from untreated cells following

155

cell lysis with 0.1% Triton X-100), as previously described (25).

156 157

Quantification of phagocytosis. HMDM and PMA-differentiated THP-1 macrophages

158

were plated at a density of 5x105 cells/well, and on the following day, cells were treated

159

with 10 µM Cytochalasin D for 30 min at 37˚C to inhibit phagocytosis if required, then

160

treated with 100 µg pHrodo Green E. coli BioParticles® Conjugate with or without

161

HDACi treatment (either priming or co-treatment). Phagocytosis was assessed at 1.5 h

162

post-treatment with pHrodo Green E. coli BioParticles® Conjugate, as measured by flow

163

cytometric quantification of fluorescence using a FACs Canto II Flow Cytometer (BD

164

Bioscience). FACs data was analysed using FlowJo 7.6.5 software (Tree Star).

165 166

Quantification of mitochondrial ROS (mitoROS). HMDM were co-treated with

167

HDACi and infected with S. Typhimurium, as above. After 6 h of infection, cells were

168

washed twice with PBS, 5 µM MitoSOXTM Red Mitochondrial Superoxide Indicator

9

169

(Life Technologies) was added, and cells were incubated for 10 min at 37˚C, before

170

mitoROS levels were quantified by flow cytometry.

171 172

Immunoblotting. Levels of specific proteins were assessed by Western Blot. Briefly,

173

cells were lysed and homogenised in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM

174

NaCl, 0.1% SDS, 1% sodium deoxycholate, 1% NP-40) supplemented with 1 x protease

175

inhibitors (Roche Life Science). Cell lysates were resolved on pre-cast 4-20% gradient

176

SDS-PAGE gels (Bio-Rad) or 4-12% Bis-Tris NuPAGE gels (Invitrogen), separated by

177

electrophoresis, and then transferred onto nitrocellulose membranes (Bio-Rad).

178

Membranes were probed using either anti-acetyl histone H3 (Cell Signaling), anti-acetyl-

179

α-tubulin (Cell Signaling) or anti-GAPDH (Trevigen) antibodies, then developed by

180

chemiluminescence (Amersham ECL Plus, GE Healthcare).

181 182

Statistics. For data combined from 3 or more independent experiments, statistical

183

analyses were performed using Prism 6 software (Graphpad), with error bars indicating

184

standard error of the mean. For data sets with 3 or more variables, a one-way ANOVA

185

analysis was performed, followed by Dunnett’s multiple comparison test. Data with

186

confidence values of ≥ 95% (p